ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - location/VIC/3002-East-Melbourne-Epworth-Freemasons
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
29
trial(s) found.
NCT07764978
Haem
Phase 3
Recruiting
Phase III Open-Label, Randomised Study of Consolidation With AZD0120 (Dual-Targeting BCMA/CD19 CAR-T) vs Continuous Standard Therapy in NDMM Patients Ineligible for ASCT as Initial Therapy (
DURGA-5
)
autologous CAR-T-cell therapy,BCMA/CD19-targeting
Multiple myeloma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2139 - Concord - Concord Repatriation General Hospital
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3002 - East Melbourne - Epworth Freemasons
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT07681596
Haem
Phase 1 / Phase 2
Recruiting
A Modular, Phase I/II, Open-label, Multicentre Study to Evaluate the Safety, Tolerability, Cellular Kinetics, and Efficacy of AZD4045, an Allogeneic Chimeric Antigen Receptor-T Cell (CAR-T) Therapy Targeting B Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma (
D7540C00001
)
allogeneic CAR-T-cell therapy,BCMA-targeting
Multiple myeloma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3002 - East Melbourne - Epworth Freemasons
NCT07491445
Advanced
Phase 3
Recruiting
RASolute 303: A Phase 3 Global, Multicenter, Open-label, Randomized, 3-Arm Study of Daraxonrasib Monotherapy or Daraxonrasib Plus Gemcitabine and Nab-paclitaxel Versus Gemcitabine and Nab-paclitaxel as a First-Line Treatment for Patients With Metastatic Pancreatic Adenocarcinoma (
RASolute-303
)
antimetabolite
pan-RAS inhibitor,tricomplex inhibitor
taxane
Pancreatic adenocarcinoma
NSW
2031 - Randwick - Prince of Wales Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3002 - East Melbourne - Epworth Freemasons
NCT07479797
Haem
Phase 3
Recruiting
A Phase 3, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy (
KT-US-740-0603
)
autologous CAR-T-cell therapy,CD19-targeting
autologous CAR-T-cell therapy,CD19/CD20-targeting
Diffuse large B-cell lymphoma
VIC
3002 - East Melbourne - Epworth Freemasons
NCT07441694
Haem
Phase 1
Recruiting
A Phase 1, Open-Label, Multicenter Study of INCA036978 in Participants With Myeloproliferative Neoplasms (
INCA036978-101
)
unknown drug class
Myeloproliferative Neoplasm
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2139 - Concord - Concord Repatriation General Hospital
VIC
3002 - East Melbourne - Epworth Freemasons
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
WA
6009 - Nedlands - Linear Clinical Research
NCT07318558
Advanced
Phase 3
Recruiting
A Phase 3, Randomized, Open-label, Multicenter Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) Maintenance Treatment With or Without Bevacizumab Versus Standard of Care in Participants With Newly Diagnosed Advanced Non-HRD Positive Ovarian Cancer Following First-line Platinum-based Chemotherapy (
TroFuse-021
/ENGOTov85/GOG-3102)
anti-Trop2 antibody-drug conjugate
anti-VEGF monoclonal antibody
Ovarian cancer
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3002 - East Melbourne - Epworth Freemasons
QLD
4120 - Greenslopes - Greenslopes Private Hospital
NCT07209111
Advanced
Phase 2
Recruiting
A Phase 2, Open-Label, Multicenter, Tumor-agnostic Study of MK-1084 as Monotherapy and in Combination With Cetuximab, in Participants With KRAS G12C-Mutant, Advanced Solid Tumors (
KANDLELIT-014
)
KRAS G12C inhibitor,OFF-state inhibitor
anti-EGFR monoclonal antibody
Cancer
NSW
2031 - Randwick - Prince of Wales Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3002 - East Melbourne - Epworth Freemasons
NCT07115043
Advanced
Phase 1 / Phase 2
Recruiting
A Phase I/II Open-label Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD6750, a CD8 Guided IL-2 Agent Alone and in Combination With Other Anti-cancer Agents in Participants With Select Advanced or Metastatic Solid Tumors (
D7350C00001
)
CD8-guided IL-2 candidate
Gastric cancer
VIC
3002 - East Melbourne - Epworth Freemasons
NCT06989112
Advanced
Phase 3
Recruiting
DESTINY-Endometrial01: An Open-Label, Sponsor-Blinded, Randomized, Controlled, Multicenter, Phase III Study of Trastuzumab Deruxtecan (T-DXd) Plus Rilvegostomig or Pembrolizumab vs Chemotherapy Plus Pembrolizumab as First-Line Therapy of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR), Primary Advanced or Recurrent Endometrial Cancer (
DE-01
)
anti-ERBB2 antibody-drug conjugate,topoisomerase inhibitor 1-payload
anti-PD-1 monoclonal antibody
bispecific PD-1/TIGIT antibody
Endometrial cancer
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
VIC
3002 - East Melbourne - Epworth Freemasons
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06952504
Advanced
Phase 3
Recruiting
A Phase 3 Randomized, Open-label, Multicenter Study to Compare the Efficacy and Safety of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone as First-line Maintenance Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (
TroFuse-033
/GOG-3119/ENGOT-en29)
anti-PD-1 monoclonal antibody
anti-Trop2 antibody-drug conjugate
Endometrial cancer
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
VIC
3002 - East Melbourne - Epworth Freemasons
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06879041
Advanced
Phase 1
Recruiting
A Phase I, First-in-human, Dose Escalation Study Of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer (
D7580C00001
)
radioligand,PSMA-targeting
Castrate-resistant prostate cancer
VIC
3002 - East Melbourne - Epworth Freemasons
NCT06824467
Advanced
Phase 3
Recruiting
A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan Maintenance Treatment With or Without Bevacizumab Versus Standard of Care After Second-line Platinum-based Doublet Chemotherapy in Participants With Platinum-sensitive Recurrent Ovarian Cancer (TroFuse-022/ENGOT-ov84/GOG-3103) (
2870-022
)
anti-Trop2 antibody-drug conjugate
anti-VEGF monoclonal antibody
High-grade serous carcinoma of the ovary, fallopian tube, and peritoneum
Ovarian cancer
Primary fallopian tube serous carcinoma
Primary peritoneal serous carcinoma
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
VIC
3002 - East Melbourne - Epworth Freemasons
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4120 - Greenslopes - Greenslopes Private Hospital
NCT06806033
Haem
Phase 2
Recruiting
A Phase II, Open-Label, Multicenter Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Patients With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma (
GO45434
)
antimetabolite
bispecific T-cell engager,CD20-targeting
platinum-based antineoplastic agent
B-cell lymphoma
VIC
3002 - East Melbourne - Epworth Freemasons
NCT06792695
Advanced
Phase 2
Recruiting
A Phase II, Open-label, Multicenter, Master Protocol to Evaluate the Safety and Efficacy of Novel Study Interventions and Combinations in Participants With Colorectal Cancer (
CANTOR
)
Bevacizumab
Fluorouracil
Irinotecan
Leucovorin
Volrustomig
anti-VEGF monoclonal antibody
antimetabolite
bispecific PD-L1/CTLA4 antibody
cancer therapy
cancer therapy,CTLA4-targeting
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PD-L1-targeting
cancer therapy,VEGF-targeting
cytotoxic chemotherapy
fluoropyrimidine
immune checkpoint blockade
immune checkpoint blockade,CTLA4-targeting
immune checkpoint blockade,PD-L1-targeting
immuno-oncology therapy,CTLA4-targeting
immuno-oncology therapy,PD-L1-targeting
immuno-oncology therapy,VEGF-targeting
therapeutic modality,bispecific antibody
topoisomerase inhibitor
Colorectal adenocarcinoma
NSW
2500 - Wollongong - Wollongong Hospital
VIC
3002 - East Melbourne - Epworth Freemasons
SA
5011 - Woodville South - The Queen Elizabeth Hospital
NCT06450106
Advanced
Phase 1
Recruiting
A Phase 1 Dose Escalation Study of STM-416p Administered Intraoperatively to Patients Undergoing Radical Prostatectomy (
STM-416p-201
)
TLR7/8 agonist
Prostate cancer
VIC
3002 - East Melbourne - Epworth Freemasons
3051 - Melbourne - Australian Prostate Centre
NCT06428409
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Study to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination With Other Anticancer Agents in Gastrointestinal Cancers (
9999-02A
)
anti-Trop2 antibody-drug conjugate
Biliary tract cancer
Colorectal cancer
Pancreatic adenocarcinoma
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3002 - East Melbourne - Epworth Freemasons
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
WA
6009 - Nedlands - One Clinical Research
NCT06267729
Advanced
Phase 1 / Phase 2
Recruiting
A Phase I/II Open Label Study to Evaluate the Safety, Cellular Kinetics, and Efficacy of AZD0754, a Chimeric Antigen Receptor (CAR) T-cell Therapy Directed Against STEAP2, in Adult Participants With Metastatic Prostate Cancer:
APOLLO
allogeneic CAR-T-cell therapy,STEAP2-targeting
Prostate cancer
VIC
3002 - East Melbourne - Epworth Freemasons
NCT06215118
Haem
Phase 1
Recruiting
A PHASE 1B, OPEN-LABEL STUDY OF ELRANATAMAB IN COMBINATION WITH IBERDOMIDE IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA (
C1071030
)
CELMoD agent
bispecific T-cell engager,BCMA-targeting
Multiple myeloma
NSW
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3002 - East Melbourne - Epworth Freemasons
3121 - Richmond - Epworth Freemasons Hospital
QLD
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
NCT06188520
Advanced
Phase 1 / Phase 2
Recruiting
A Phase I/IIa, First-in-human, Open-label, Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors (
CYCAD-1
)
CDK2 inhibitor
Breast cancer
High-grade serous ovarian cancer
VIC
3002 - East Melbourne - Epworth Freemasons
NCT06091865
Haem
Phase 3
Recruiting
A Phase 3, Open Label, Randomized Study Comparing the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 \xD7 Anti-CD3 Bispecific Antibody, in Combination With CHOP (ODRO-CHOP) Versus Rituximab in Combination With CHOP (R-CHOP) in Previously Untreated Participants With Diffuse Large B-cell Lymphoma (DLBCL) (
OLYMPIA-3
)
anti-CD20 monoclonal antibody
bispecific T-cell engager,CD20-targeting
Diffuse large B-cell lymphoma
NSW
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3002 - East Melbourne - Epworth Freemasons
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
4217 - Benowa - Pindara Private Hospital
NCT06057402
Haem
Phase 4
Recruiting
ELRANATAMAB POST TRIAL ACCESS: AN OPEN-LABEL, SINGLE-ARM STUDY FOR PARTICIPANTS WITH MULTIPLE MYELOMA CONTINUING FROM PFIZER-SPONSORED ELRANATAMAB CLINICAL STUDIES (
MagnetisMM15
)
bispecific T-cell engager,BCMA-targeting
Multiple myeloma
VIC
3002 - East Melbourne - Epworth Freemasons
3121 - Richmond - Epworth Freemasons Hospital
NCT05827081
Curative
Phase 3
Recruiting
A Phase IIIb Study to Characterize the Efficacy and Safety of Adjuvant Ribociclib Plus Endocrine Therapy in a Close-to-clinical Practice Patient Population With HR+ HER2- Early Breast Cancer (Adjuvant WIDER) (
Adjuvant-WIDER
)
CDK4/6 inhibitor
Breast cancer
NT
0810 - Tiwi, Royal Darwin Hospital - Northern Centre for Oncology
NSW
2290 - Gateshead - Genesis Cancer Care, Lake Macquarie Private Hospital
VIC
3002 - East Melbourne - Epworth Freemasons
3168 - Clayton - Monash Medical Centre
NCT05623020
Haem
Phase 3
Recruiting
AN OPEN-LABEL, 2-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) + DARATUMUMAB + LENALIDOMIDE VERSUS DARATUMUMAB + BORTEZOMIB + LENALIDOMIDE + DEXAMETHASONE IN TRANSPLANT-INELIGIBLE PARTICIPANTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (
MagnetisMM-6
)
anti-CD38 monoclonal antibody
bispecific T-cell engager,BCMA-targeting
glucocorticoid
immunomodulatory imide drug
proteasome inhibitor
Multiple myeloma
VIC
3002 - East Melbourne - Epworth Freemasons
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
3121 - Richmond - Epworth Freemasons Hospital
QLD
4217 - Benowa - Pindara Private Hospital
NZ
NZ.0622 - Takapuna - North Shore Hospital
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.3210 - Hamilton - Waikato Hospital
NCT05128825
Advanced
Phase 2
Recruiting
A Phase 2 Open-Label, Multicenter Study To Evaluate Efficacy And Safety Of ZN-c3 In Subjects With High-Grade Serous Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer (
DENALI
/ ZN-c3-005 / GOG-3066)
WEE1 inhibitor
High-grade serous ovarian cancer
Ovarian cancer
Primary fallopian tube serous carcinoma
Primary peritoneal serous carcinoma
VIC
3002 - East Melbourne - Epworth Freemasons
QLD
4032 - Chermside - Icon Cancer Care Chermside
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
5065 - Toorak Gardens - Burnside War Memorial Hospital
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT05020236
Haem
Phase 3
Recruiting
AN OPEN-LABEL, 3-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) MONOTHERAPY AND ELRANATAMAB + DARATUMUMAB VERSUS DARATUMUMAB + POMALIDOMIDE + DEXAMETHASONE IN PARTICIPANTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST 1 PRIOR LINE OF THERAPY INCLUDING LENALIDOMIDE AND A PROTEASOME INHIBITOR (
MAGNETISMM-5
)
anti-CD38 monoclonal antibody
bispecific T-cell engager,BCMA-targeting
glucocorticoid
immunomodulatory imide drug
Multiple myeloma
VIC
3002 - East Melbourne - Epworth Freemasons
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
3121 - Richmond - Epworth Freemasons Hospital
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
4120 - Greenslopes - Greenslopes Private Hospital
4217 - Benowa - Pindara Private Hospital
WA
6009 - Nedlands - Linear Clinical Research
NZ
NZ.0622 - Takapuna - North Shore Hospital
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.3210 - Hamilton - Waikato Hospital
NZ.4442 - Roslyn - Palmerston North Hospital Cancer Centre - Palmerston North Hospital
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NCT04989803
Haem
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Open-label, Multicenter Study Evaluating the Safety and Efficacy of KITE-363 or KITE-753, Autologous Anti-CD19/CD20 CAR T-cell Therapies, in Subjects With Relapsed and/or Refractory B-cell Lymphoma (
PALISADES-1
)
autologous CAR-T-cell therapy,CD19/CD20-targeting
B-cell lymphoma
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2139 - Concord - Concord Repatriation General Hospital
VIC
3002 - East Melbourne - Epworth Freemasons
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT03093116
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (
TRIDENT-1
)
ALK inhibitor,third generation
ROS1 inhibitor
TRK inhibitor,second generation
Non-small cell lung cancer
Solid tumour
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3002 - East Melbourne - Epworth Freemasons
SA
5042 - Bedford Park - Flinders Medical Centre
ACTRN12624000288527
Advanced
Phase 3
Recruiting
Efficacy of intraperitoneal bevacizumab for decreasing or delaying re-accumulation of recurrent malignant ascites in chemotherapy resistant solid tumours: a randomised trial (
REZOLV3R
)
anti-VEGF monoclonal antibody
Solid tumour
NSW
2060 - North Sydney - Mater Hospital
2139 - Concord - Concord Repatriation General Hospital
VIC
3002 - East Melbourne - Epworth Freemasons
3677 - Wangaratta - Northeast Health Wangaratta
SA
5042 - Bedford Park - Flinders Medical Centre
ACTRN12624000005550
Curative
Phase 3
Recruiting
Efficacy of Neoadjuvant FOLFIRINOX in Resectable pancreatic cancer: An international multicenter prospective randomized, controlled trial (
NeoFOL-R
)
Filgrastim
Fluorouracil
Irinotecan
Leucovorin
Oxaliplatin
antimetabolite
cancer therapy
cytotoxic chemotherapy
fluoropyrimidine
platinum-based antineoplastic agent
topoisomerase inhibitor
Pancreatic cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3002 - East Melbourne - Epworth Freemasons
3004 - Melbourne, Southbank - Alfred Health
3011 - Footscray - Footscray Hospital
3066 - Epping - Northern Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3121 - Richmond - Epworth Freemasons Hospital
3168 - Clayton - Monash Medical Centre
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (29)
Recruitment Country and State
VIC (29)
NSW (18)
QLD (11)
WA (7)
SA (5)
NZ (2)
NT (1)
Phase
Phase 1 (4)
Phase 1 / Phase 2 (7)
Phase 2 (4)
Phase 3 (13)
Phase 4 (1)
Trial Type
Advanced (16)
Haem (11)
Curative (2)
Cancer Therapy Class
BCMA
17%
PD-1/PD-L1
17%
CD38
14%
cereblon
14%
CD20
14%
Trop2
14%
VEGF
14%
PD-1
14%
proteasome
7%
KRAS
7%
CD19
7%
TIGIT
7%
CDK4
7%
CDK6
7%
oestrogen axis
7%
IL-2
3%
EGFR
3%
ERBB2
3%
PSMA
3%
CTLA4
3%
PD-L1
3%
STEAP2
3%
CDK2
3%
ER
3%
GnRH
3%
androgen axis
3%
WEE1
3%
ALK
3%
ROS1
3%
TRK
3%
Facility
3002 - East Melbourne - Epworth Freemasons (29)
3121 - Richmond - Epworth Freemasons Hospital (5)
2139 - Concord - Concord Repatriation General Hospital (4)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (4)
3004 - Melbourne, Southbank - Alfred Health (4)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (4)
2170 - Liverpool - Liverpool Hospital (3)
3065 - Fitzroy - St Vincent's Hospital Melbourne (3)
2050 - Camperdown - Chris O'Brien Lifehouse (3)
4120 - Greenslopes - Greenslopes Private Hospital (3)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (3)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (3)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (3)
4217 - Benowa - Pindara Private Hospital (3)
2031 - Randwick - Prince of Wales Hospital (2)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (2)
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital (2)
6009 - Nedlands - Linear Clinical Research (2)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (2)
3199 - Frankston - Peninsula Health Frankston Hospital (2)
3168 - Clayton - Monash Medical Centre (2)
NZ.0622 - Takapuna - North Shore Hospital (2)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (2)
NZ.3210 - Hamilton - Waikato Hospital (2)
5042 - Bedford Park - Flinders Medical Centre (2)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (1)
6150 - Murdoch - Fiona Stanley Hospital (1)
2500 - Wollongong - Wollongong Hospital (1)
5011 - Woodville South - The Queen Elizabeth Hospital (1)
3051 - Melbourne - Australian Prostate Centre (1)
6009 - Nedlands - One Clinical Research (1)
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital (1)
0810 - Tiwi, Royal Darwin Hospital - Northern Centre for Oncology (1)
2290 - Gateshead - Genesis Cancer Care, Lake Macquarie Private Hospital (1)
4032 - Chermside - Icon Cancer Care Chermside (1)
5037 - Kurralta Park - Icon Cancer Centre Adelaide (1)
5065 - Toorak Gardens - Burnside War Memorial Hospital (1)
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital (1)
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong (1)
4102 - Woolloongabba - Princess Alexandra Hospital (1)
NZ.4442 - Roslyn - Palmerston North Hospital Cancer Centre - Palmerston North Hospital (1)
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital (1)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (1)
3000 - Melbourne - Peter MacCallum Cancer Centre (1)
2060 - North Sydney - Mater Hospital (1)
3677 - Wangaratta - Northeast Health Wangaratta (1)
3011 - Footscray - Footscray Hospital (1)
3066 - Epping - Northern Hospital (1)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (1)
Cancer Type
Cancer
Solid tumour
Haematological malignancy
Multiple myeloma
Plasma cell disorder
Gynaecological cancer
Gastrointestinal cancer
Upper gastrointestinal cancer
B-cell lymphoma
B-cell malignancy
Lymphoma
Mature B-cell malignancy
Non-Hodgkin's lymphoma
Ovarian cancer
Pancreatic cancer
Pancreatobiliary cancer
Male genital cancers
Prostate cancer
Urogenital cancer
Epithelial Ovarian Cancer
High-grade serous carcinoma of the ovary, fallopian tube, and peritoneum
Exocrine pancreatic cancer
Pancreatic adenocarcinoma
Diffuse large B-cell lymphoma
High-grade B-cell lymphoma
Endometrial cancer
Fallopian tube cancer
Peritoneal cancer
Primary fallopian tube serous carcinoma
Primary peritoneal serous carcinoma
Colorectal cancer
Lower gastrointestinal cancer
Breast cancer
High-grade serous ovarian cancer
Ovarian adenocarcinoma
Ovarian serous carcinoma
Myeloproliferative neoplasm
Gastric cancer
Gastroesophageal cancer
Castrate-resistant prostate cancer
Prostate adenocarcinoma
Colorectal adenocarcinoma
Biliary tract cancer
Hepatobiliary cancer
Lung cancer
Non-small cell lung cancer
Respiratory tract cancer
Thoracic cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy